Pfizer v. Biocon: Xeljanz XR Tofacitinib Suit Dismissed Without Prejudice in 75 Days
Pfizer and four affiliated entities filed suit against Biocon and two subsidiaries in the Delaware District Court over U.S. Reissue Patent RE41,783, covering Xeljanz XR tofacitinib citrate extended-release tablets at 11 mg and 22 mg dosage strengths. The case closed just 75 days after filing when Pfizer invoked Rule 41(a)(1)(A)(i) to dismiss all claims without prejudice — before Biocon filed any answer.
A 75-day opening salvo: Pfizer retreats without burning its legal bridges
On 26 June 2024, Pfizer Inc. together with PF Prism C.V., C.P. Pharmaceuticals International C.V., PBG Puerto Rico LLC, and PF Prism IMB C.V. filed an infringement action in the Delaware District Court against Biocon Ltd., Biocon Pharma Inc., and Biocon Pharma Limited. The suit centred on U.S. Reissue Patent RE41,783 and alleged infringement through Biocon’s efforts to commercialise generic versions of Xeljanz XR — Pfizer’s extended-release tofacitinib formulation sold at 11 mg and 22 mg strengths.
The case closed on 9 September 2024 when Pfizer filed a notice of voluntary dismissal without prejudice under Federal Rule of Civil Procedure 41(a)(1)(A)(i). That procedural route is available only before the defendant serves an answer or a motion for summary judgment, and the docket confirms Biocon had done neither. The dismissal is unilateral, requires no court order, and leaves all claims legally intact — Pfizer retains the right to re-file the same infringement action at any future time.
A resolution within 75 days of filing, before any substantive pleadings from the defence, is unusual even by the standards of pharmaceutical patent litigation, where pre-trial skirmishes routinely extend for years. The speed and pre-answer timing suggest the parties may have reached a commercial accommodation — such as a licensing agreement or a consent framework — that made continued litigation unnecessary, though no settlement terms appear on the public record. The without-prejudice posture preserves Pfizer’s enforcement leverage entirely, meaning the patent remains a live threat to any Biocon generic launch.
Filing to Dismissed without Prejudice in 75 days
75 days — notably short for a ANDA/Hatch-Waxman patent dispute in Delaware
Dismissed without prejudice: what Rule 41 means for both parties
Rule 41(a)(1)(A)(i) allows unilateral exit before any answer
Federal Rule of Civil Procedure 41(a)(1)(A)(i) permits a plaintiff to dismiss an action as of right — without a court order — provided the defendant has not yet served an answer or a motion for summary judgment. Because Biocon had done neither, Pfizer’s notice was self-executing and took immediate effect on filing. No judicial approval was required, and no merits determination was made.
No court order requiredClaims survive: Pfizer keeps full re-filing rights
A without-prejudice dismissal does not extinguish the underlying claims. Pfizer and its co-plaintiffs remain free to assert USRE041783E against Biocon in a future action, whether in Delaware or another venue. The patent’s enforceability is entirely unaffected. For Biocon, this means the infringement risk attached to any generic tofacitinib launch has not been resolved — it has merely been paused.
Claims preserved; risk unresolvedNo admission, no victory — Biocon gains no defensive precedent
Because the case ended before Biocon served any pleading, there is no invalidity ruling, no non-infringement finding, and no licence on the public record. Biocon cannot cite this outcome as a precedent or a legal shield in future proceedings. Any commercial relief the company may have obtained — if a private arrangement exists — is not publicly visible and carries no formal legal weight.
No merits adjudicationUSRE041783E remains an active barrier to generic Xeljanz XR entry
The reissue patent covering tofacitinib citrate extended-release formulation retains its full presumption of validity. Generic manufacturers — including Biocon — must treat it as a live enforcement asset. The 75-day lifecycle and pre-answer withdrawal are consistent with a confidential licensing or launch-date agreement, a pattern common in Hatch-Waxman litigation. Until the patent expires or is invalidated, the 11 mg and 22 mg dosage strengths remain legally protected.
Patent enforcement risk persistsFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Pfizer, Inc. | Company | Global biopharmaceutical company — holder of USRE041783E covering Xeljanz XR tofacitinib ER tabletsSearch in Eureka ↗ |
| Co-Plaintiff | PF Prism C.V. | Individual | Search in Eureka ↗ |
| Co-Plaintiff | C.P. Pharmaceuticals International C.V. | Individual | Search in Eureka ↗ |
| Co-Plaintiff | Pbg Puerto Rico, LLC | Company | Search in Eureka ↗ |
| Co-Plaintiff | PF Prism Ibm C.V. | Individual | Search in Eureka ↗ |
| Defendant | Biocon, Ltd. | Company | Biocon Ltd. and subsidiaries — Indian biopharmaceutical group seeking to market generic tofacitinibSearch in Eureka ↗ |
| Co-Defendant | Biocon Pharma, Inc. | Company | Search in Eureka ↗ |
| Co-Defendant | Biocon Pharma Limited | Individual | Search in Eureka ↗ |
| Plaintiff counsel | Jack B. Blumenfeld | Attorney | Counsel for Pfizer, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Megan Elizabeth Dellinger | Attorney | Counsel for Pfizer, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Morris, Nichols, Arsht & Tunnell LLP | Law Firm | Representing Pfizer, Inc.Search in Eureka ↗ |
| Defendant counsel | R. Touhey Myer. | Attorney | Counsel for Biocon, Ltd.Search in Eureka ↗ |
| Defendant law firm | Kratz & Barry LLP | Law Firm | Representing Biocon, Ltd.Search in Eureka ↗ |
| Presiding judge | Judge Colm F. Connolly | Judge | Delaware District CourtSearch in Eureka ↗ |
Official order — verbatim text
The dismissal notice explicitly invokes Rule 41(a)(1)(A)(i) and confirms on the face of the record that no answer or summary judgment motion had been served by any Biocon entity. This procedural posture is dispositive: the dismissal is without prejudice as a matter of law, not as a matter of judicial discretion. No claim has been adjudicated on the merits. The patent’s validity, scope, and enforceability are legally unchanged, and Pfizer’s right to re-assert RE41,783 against Biocon or any other party remains intact.
USRE041783E — Tofacitinib citrate extended-release tablet formulation
U.S. Reissue Patent RE41,783 (corrected application number 12/577,790) covers the formulation of tofacitinib citrate in an extended-release oral dosage form — the technology underlying Pfizer’s Xeljanz XR product at 11 mg and 22 mg strengths. As a reissue patent, RE41,783 has undergone USPTO reexamination to correct defects in the original grant, a process that generally narrows claims but also reinforces their validity by surviving a second round of PTO scrutiny. Tofacitinib is a JAK inhibitor approved for rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis.
The commercial significance of RE41,783 is substantial: Xeljanz XR represents a key revenue line for Pfizer in the immunology space, and the extended-release formulation differentiates the product from immediate-release Xeljanz in both dosing convenience and patent timeline. A reissue patent covering the ER formulation gives Pfizer a distinct enforcement asset beyond any compound patent, potentially extending exclusivity further into the product lifecycle. For generic manufacturers and biosimilar developers in the JAK inhibitor segment, this patent represents a high-priority clearance target.
Should your team run an FTO analysis against USRE041783E?
Any company holding or pursuing an ANDA for tofacitinib citrate extended-release tablets — at 11 mg, 22 mg, or adjacent dosage strengths — should treat RE41,783 as a primary freedom-to-operate concern. The reissue designation means the claims have been revised under USPTO oversight, which can shift claim scope in ways that affect previously conducted clearance analyses. R&D teams developing ER formulations of JAK inhibitors more broadly should also assess whether the claimed formulation parameters create design-around constraints.
PatSnap Eureka’s FTO Search Agent allows you to map the claim landscape of RE41,783 against your own formulation data, identify prosecution history estoppel, and benchmark against related Orange Book-listed patents in the tofacitinib family. Eureka can also flag any continuation or divisional applications that may extend the patent family’s reach beyond the reissue grant, giving your IP and regulatory teams a consolidated risk picture before any launch decision.
Run a freedom-to-operate analysis on USRE041783E to assess your product’s exposure
Run FTO in Eureka →Similar JAK inhibitor and ANDA patent cases in Delaware District Court
Cases involving Hatch-Waxman infringement suits over JAK inhibitor and small-molecule ER formulation patents filed in Delaware District Court.
What this case signals for the tofacitinib and JAK inhibitor IP landscape
Pfizer’s rapid, without-prejudice withdrawal before any defence pleading is a recognised Hatch-Waxman litigation tactic with significant commercial implications.
Pre-answer withdrawal is a classic settlement signal in ANDA litigation
When a brand pharmaceutical plaintiff dismisses without prejudice under Rule 41(a)(1)(A)(i) before the defendant answers, it typically signals that the parties have reached a private commercial arrangement — such as an authorised generic deal, a consent judgement, or a negotiated launch date. IP teams monitoring the tofacitinib space should treat this outcome as a potential licensed-entry signal rather than a clean competitive opening.
USRE041783E is unimpaired and actionable against other generic filers
The voluntary dismissal leaves RE41,783 with its full presumptive validity intact. Any other generic manufacturer holding an ANDA for tofacitinib citrate extended-release tablets at 11 mg or 22 mg should assess its exposure to this reissue patent. Pfizer has demonstrated willingness to enforce aggressively in Delaware, and reissue patents — which have already survived one USPTO review — typically present a higher litigation bar for challengers.
Pfizer v Biocon — key questions answered
A dismissal without prejudice under Rule 41(a)(1)(A)(i) means no claims were adjudicated on the merits. Pfizer retains the full right to re-file the same infringement action asserting USRE041783E against Biocon at any time. The patent’s validity and enforceability are legally unchanged by this outcome.
USRE041783E is a U.S. reissue patent covering tofacitinib citrate in an extended-release oral formulation — the technology behind Pfizer’s Xeljanz XR at 11 mg and 22 mg. As a reissue patent it has survived a second USPTO review, which typically strengthens its presumptive validity and raises the challenge bar for generic ANDA filers.
The public record does not disclose a reason. However, a pre-answer voluntary dismissal within 75 days is consistent with a confidential commercial resolution — such as a licensing agreement, consent framework, or negotiated launch date — a common pattern in Hatch-Waxman litigation. No settlement terms appear on the docket.
Not necessarily. The dismissal without prejudice does not grant Biocon a licence or a non-infringement finding. Any launch would still be subject to USRE041783E, the applicable 30-month Hatch-Waxman stay timeline, FDA approval status, and any undisclosed private agreement between the parties. Competitors should monitor FDA Orange Book listings for updated patent and exclusivity data.
The case was filed in the United States District Court for the District of Delaware and assigned to Chief Judge Colm F. Connolly. Pfizer was represented by Morris, Nichols, Arsht & Tunnell LLP (Jack B. Blumenfeld and Megan Elizabeth Dellinger); Biocon was represented by Kratz & Barry LLP (R. Touhey Myer).
PatSnap Eureka searches patents and litigation data to answer instantly.